June 22, 2020
Rexgenero Acquires Aratinga.bio SAS Group's Key Technology and Program Assets
June 22, 2020—Rexgenero Ltd., a United Kingdom-based regenerative medicine company developing cell therapies to treat chronic limb-threatening ischemia, announced the acquisition of all the key assets of aratinga.bio SAS Group, a preclinical-stage immunotherapy biotech company based in Paris, France.
According to Rexgenero, the acquisition, which follows the recent approval by the French Commercial Court, includes all patent applications and related intellectual property (IP), the exclusive license agreement for polymeric nanoparticle technology, and the bioproduction facilities of aratinga.bio as well as the entire aratinga.bio team. All assets of aratinga.bio will be transferred to a newly created French subsidiary of Rexgenero.
In Rexgenero's announcement, the company's chairman David Horn Solomon, PhD, commented, “The acquisition of the aratinga.bio SAS Group’s assets and IP will enable the creation of an integrated cell and gene therapy platform that combines our innovative late-stage Phase III REX-001 program for chronic limb-threatening ischemia with aratinga.bio SAS Group’s potentially transformative in vivo CAR-T platform. In addition, the operating synergies between the two businesses are considerable.”
Renaud Vaillant, Chief Executive Officer of aratinga.bio SAS Group, stated, “This unique combination provides the solution we have been looking for, enabling us to continue the development of our breakthrough CAR-T technology to proof of concept in 2020 in preparation for a Phase I/II clinical trial.” Cécile Bauche, aratinga.bio's Chief Scientific Officer, added, “This acquisition will provide funding for experiments needed to demonstrate proof of concept of our CAR-T therapeutics in vivo.”
The transaction enables aratinga.bio to continue the development of its technology, and for its team of 15 people to pursue this program in Villejuif, close to the Institut Gustave Roussy outside of Paris.